Physician profile
Grant Randall
NPI 1245793728
$4,215.92
in general payments reported to CMS, 2019-2025
21 companies · $1,844 in 2025
The $1,844 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $21.80 · 2021: $322 · 2022: $222 · 2023: $687 · 2024: $1,119 · 2025: $1,844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,634 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,634.40 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $849.13 | 2021-2025 | |
| Abbvie INC. | $716.18 | 2021-2025 | |
| Lilly USA, LLC | $415.60 | 2022-2025 | Ebglyss, Taltz, Olumiant |
| Mayne Pharma Commercial LLC | $300.86 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $259.04 | 2021-2025 | |
| Amgen INC. | $252.25 | 2020-2025 | Otezla, Otezla |
| Ucb, INC. | $237.03 | 2024-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $158.45 | 2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $152.79 | 2024-2025 | Sotyktu |
| Leo Pharma INC. | $137.64 | 2024 | Adbry |
| Regeneron Healthcare Solutions, INC. | $128.83 | 2024-2025 | Dupixent |
| Regeneron Pharmaceuticals, INC. | $123.76 | 2023 | Dupixent |
| Novartis Pharmaceuticals Corporation | $122.07 | 2024-2025 | |
| Incyte Corporation | $99.68 | 2024-2025 | Opzelura |
| Janssen Biotech, INC. | $76.94 | 2024-2025 | Tremfya |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $60.66 | 2024-2025 | Zoryve |
| Pfizer INC. | $54.54 | 2023-2025 | |
| Almirall LLC | $27.30 | 2025 | Seysara |
| Ani Pharmaceuticals, INC. | $19.53 | 2025 | Purified Cortrophin Gel |
| Biofrontera INC. | $12.24 | 2024 | Ameluz, Rhodoled Xl, Xepi |
| Organon LLC | $11.40 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grant Randall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.